Delisting riskPopularity #5,097
20/20 Biolabs (AIDX)
Blood testing for cancer screening and inflammation tracking, plus laboratory services for diagnostic developers.
$0.4689
After hours−0.00 (−0.34%)
At close$0.4705(+0.13%)
Something off on this page? Send us feedback.
EPSReportedEstimate
—————Mar '26May '26Aug '26
Reported—————−$0.25−$0.28−$0.26
Estimate——————−$0.10−$0.12
Surprise——————−180.0%−116.7%
RevenueReportedEstimate
—————Mar '26May '26Aug '26
Reported—————$538.0K$353.4K$730.6K
Estimate——————$779.0K$636.0K
Surprise——————−54.6%+14.9%
HistoryUpcoming
| Date / Period | Estimate | Reported | Surprise |
|---|---|---|---|
| Dec 2026 | −$0.07 | — | — |
| Sep 2026 | −$0.06 | — | — |
| Aug 2026 | −$0.12 | −$0.26 | −116.7% |
| May 2026 | −$0.10 | −$0.28 | −180.0% |
| Mar 2026 | — | −$0.25 | — |
| Date / Period | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Dec 2026 | −$0.07 | — | — | $1.1M | — | — | — |
| Sep 2026 | −$0.06 | — | — | $891.0K | — | — | — |
| Aug 14, 2026 | −$0.12 | −$0.26 | −116.7% | $636.0K | $730.6K | +14.9% | +5.9% |
| May 20, 2026 | −$0.10 | −$0.28 | −180.0% | $779.0K | $353.4K | −54.6% | −3.7% |
| Mar 31, 2026 | — | −$0.25 | — | — | $538.0K | — | 0.0% |